The clinicopathological relevance of pretransplant anti-angiotensin II type 1 receptor antibodies in renal transplantation

KNOW-KT on behalf of the Study Group

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background: Anti-angiotensin II type 1 receptor antibodies (AT1R-Abs) have been suggested as a risk factor for graft failure and acute rejection (AR). However, the prevalence and clinical significance of pretransplant AT1R-Abs have seldom been evaluated in Asia. Methods: In this multicenter, observational cohort study, we tested the AT1R-Abs in pretransplant serum samples obtained from 166 kidney transplant recipients. Statistical analysis was used to set a threshold AT1R-Abs level at 9.05 U/mL. Results: Pretransplant AT1R-Abs were detected in 98/166 (59.0%) of the analyzed recipients. No graft loss or patient death was reported during the study period. AT1R-Abs (+) patients had a significantly higher incidence of biopsy-proven AR than AT1R-Abs (-) patients (27.6 versus 10.3%, P = 0.007). Recipients with pretransplant AT1R-Abs had a 3.2-fold higher risk of AR within a year of transplantation (P = 0.006). Five study subjects developed microcirculation inflammation (score ≥our of them were presensitized to AT1R-Abs. In particular, three patients had a high titer of anti-AT1R-Abs (> U/mL). Conclusions: Pretransplant AT1R-Abs is an independent risk factor for AR, especially acute cellular rejection, and is possibly associated with the risk of antibody-mediated injury. Pretransplant assessment of AT1R-Abs may be useful for stratifying immunologic risks.

Original languageEnglish
Pages (from-to)1244-1250
Number of pages7
JournalNephrology Dialysis Transplantation
Volume32
Issue number7
DOIs
Publication statusPublished - 2017 Jul

Fingerprint

Angiotensin Type 1 Receptor
Kidney Transplantation
Antibodies
Transplants
Microcirculation
Observational Studies

All Science Journal Classification (ASJC) codes

  • Nephrology
  • Transplantation

Cite this

@article{2525f32a691148cb8c3faaf9f77a0867,
title = "The clinicopathological relevance of pretransplant anti-angiotensin II type 1 receptor antibodies in renal transplantation",
abstract = "Background: Anti-angiotensin II type 1 receptor antibodies (AT1R-Abs) have been suggested as a risk factor for graft failure and acute rejection (AR). However, the prevalence and clinical significance of pretransplant AT1R-Abs have seldom been evaluated in Asia. Methods: In this multicenter, observational cohort study, we tested the AT1R-Abs in pretransplant serum samples obtained from 166 kidney transplant recipients. Statistical analysis was used to set a threshold AT1R-Abs level at 9.05 U/mL. Results: Pretransplant AT1R-Abs were detected in 98/166 (59.0{\%}) of the analyzed recipients. No graft loss or patient death was reported during the study period. AT1R-Abs (+) patients had a significantly higher incidence of biopsy-proven AR than AT1R-Abs (-) patients (27.6 versus 10.3{\%}, P = 0.007). Recipients with pretransplant AT1R-Abs had a 3.2-fold higher risk of AR within a year of transplantation (P = 0.006). Five study subjects developed microcirculation inflammation (score ≥our of them were presensitized to AT1R-Abs. In particular, three patients had a high titer of anti-AT1R-Abs (> U/mL). Conclusions: Pretransplant AT1R-Abs is an independent risk factor for AR, especially acute cellular rejection, and is possibly associated with the risk of antibody-mediated injury. Pretransplant assessment of AT1R-Abs may be useful for stratifying immunologic risks.",
author = "{KNOW-KT on behalf of the Study Group} and Juhan Lee and Huh, {Kyu Ha} and Yongjung Park and Park, {Borae G.} and Jaeseok Yang and Jeong, {Jong Cheol} and Joongyup Lee and Park, {Jae Berm} and Cho, {Jang Hee} and Sik Lee and Han Ro and Han, {Seung Yeup} and Kim, {Myoung Soo} and Kim, {Yu Seun} and Kim, {Sung Joo} and Kim, {Chan Duck} and Wookyung Chung and Park, {Sung Bae} and Curie Ahn and Jung, {Hee Yeon} and Eunah Hwang and Wooyeong Park and Park, {Byung Joo}",
year = "2017",
month = "7",
doi = "10.1093/ndt/gfv375",
language = "English",
volume = "32",
pages = "1244--1250",
journal = "Nephrology Dialysis Transplantation",
issn = "0931-0509",
publisher = "Oxford University Press",
number = "7",

}

The clinicopathological relevance of pretransplant anti-angiotensin II type 1 receptor antibodies in renal transplantation. / KNOW-KT on behalf of the Study Group.

In: Nephrology Dialysis Transplantation, Vol. 32, No. 7, 07.2017, p. 1244-1250.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The clinicopathological relevance of pretransplant anti-angiotensin II type 1 receptor antibodies in renal transplantation

AU - KNOW-KT on behalf of the Study Group

AU - Lee, Juhan

AU - Huh, Kyu Ha

AU - Park, Yongjung

AU - Park, Borae G.

AU - Yang, Jaeseok

AU - Jeong, Jong Cheol

AU - Lee, Joongyup

AU - Park, Jae Berm

AU - Cho, Jang Hee

AU - Lee, Sik

AU - Ro, Han

AU - Han, Seung Yeup

AU - Kim, Myoung Soo

AU - Kim, Yu Seun

AU - Kim, Sung Joo

AU - Kim, Chan Duck

AU - Chung, Wookyung

AU - Park, Sung Bae

AU - Ahn, Curie

AU - Jung, Hee Yeon

AU - Hwang, Eunah

AU - Park, Wooyeong

AU - Park, Byung Joo

PY - 2017/7

Y1 - 2017/7

N2 - Background: Anti-angiotensin II type 1 receptor antibodies (AT1R-Abs) have been suggested as a risk factor for graft failure and acute rejection (AR). However, the prevalence and clinical significance of pretransplant AT1R-Abs have seldom been evaluated in Asia. Methods: In this multicenter, observational cohort study, we tested the AT1R-Abs in pretransplant serum samples obtained from 166 kidney transplant recipients. Statistical analysis was used to set a threshold AT1R-Abs level at 9.05 U/mL. Results: Pretransplant AT1R-Abs were detected in 98/166 (59.0%) of the analyzed recipients. No graft loss or patient death was reported during the study period. AT1R-Abs (+) patients had a significantly higher incidence of biopsy-proven AR than AT1R-Abs (-) patients (27.6 versus 10.3%, P = 0.007). Recipients with pretransplant AT1R-Abs had a 3.2-fold higher risk of AR within a year of transplantation (P = 0.006). Five study subjects developed microcirculation inflammation (score ≥our of them were presensitized to AT1R-Abs. In particular, three patients had a high titer of anti-AT1R-Abs (> U/mL). Conclusions: Pretransplant AT1R-Abs is an independent risk factor for AR, especially acute cellular rejection, and is possibly associated with the risk of antibody-mediated injury. Pretransplant assessment of AT1R-Abs may be useful for stratifying immunologic risks.

AB - Background: Anti-angiotensin II type 1 receptor antibodies (AT1R-Abs) have been suggested as a risk factor for graft failure and acute rejection (AR). However, the prevalence and clinical significance of pretransplant AT1R-Abs have seldom been evaluated in Asia. Methods: In this multicenter, observational cohort study, we tested the AT1R-Abs in pretransplant serum samples obtained from 166 kidney transplant recipients. Statistical analysis was used to set a threshold AT1R-Abs level at 9.05 U/mL. Results: Pretransplant AT1R-Abs were detected in 98/166 (59.0%) of the analyzed recipients. No graft loss or patient death was reported during the study period. AT1R-Abs (+) patients had a significantly higher incidence of biopsy-proven AR than AT1R-Abs (-) patients (27.6 versus 10.3%, P = 0.007). Recipients with pretransplant AT1R-Abs had a 3.2-fold higher risk of AR within a year of transplantation (P = 0.006). Five study subjects developed microcirculation inflammation (score ≥our of them were presensitized to AT1R-Abs. In particular, three patients had a high titer of anti-AT1R-Abs (> U/mL). Conclusions: Pretransplant AT1R-Abs is an independent risk factor for AR, especially acute cellular rejection, and is possibly associated with the risk of antibody-mediated injury. Pretransplant assessment of AT1R-Abs may be useful for stratifying immunologic risks.

UR - http://www.scopus.com/inward/record.url?scp=84996994689&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84996994689&partnerID=8YFLogxK

U2 - 10.1093/ndt/gfv375

DO - 10.1093/ndt/gfv375

M3 - Article

C2 - 26546592

AN - SCOPUS:84996994689

VL - 32

SP - 1244

EP - 1250

JO - Nephrology Dialysis Transplantation

JF - Nephrology Dialysis Transplantation

SN - 0931-0509

IS - 7

ER -